Pharming Common Stock Shares Outstanding vs Total Current Liabilities Analysis

PHAR Stock  USD 9.27  0.53  6.06%   
Pharming Group financial indicator trend analysis is much more than just breaking down Pharming Group NV prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pharming Group NV is a good investment. Please check the relationship between Pharming Group Common Stock Shares Outstanding and its Total Current Liabilities accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Common Stock Shares Outstanding vs Total Current Liabilities

Common Stock Shares Outstanding vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pharming Group NV Common Stock Shares Outstanding account and Total Current Liabilities. At this time, the significance of the direction appears to have very week relationship.
The correlation between Pharming Group's Common Stock Shares Outstanding and Total Current Liabilities is 0.25. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Pharming Group NV, assuming nothing else is changed. The correlation between historical values of Pharming Group's Common Stock Shares Outstanding and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Pharming Group NV are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Common Stock Shares Outstanding i.e., Pharming Group's Common Stock Shares Outstanding and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.25
Relationship DirectionPositive 
Relationship StrengthVery Weak

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Current Liabilities

Total Current Liabilities is an item on Pharming Group balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Pharming Group NV are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most indicators from Pharming Group's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pharming Group NV current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
At this time, Pharming Group's Selling General Administrative is relatively stable compared to the past year. As of 12/11/2024, Issuance Of Capital Stock is likely to grow to about 4 M, while Tax Provision is likely to drop (1.5 M).
 2021 2022 2023 2024 (projected)
Total Operating Expenses156.7M169.8M225.5M236.8M
Cost Of Revenue20.2M17.6M25.2M15.2M

Pharming Group fundamental ratios Correlations

0.980.920.640.970.90.190.380.230.70.760.96-0.180.980.910.660.580.950.860.620.880.970.990.090.81-0.37
0.980.920.590.920.870.090.390.190.710.770.94-0.210.960.850.610.540.980.850.560.860.980.970.050.83-0.38
0.920.920.680.830.720.190.39-0.010.80.690.9-0.220.90.850.620.540.910.780.560.830.960.910.150.78-0.42
0.640.590.680.520.350.510.17-0.260.670.490.80.060.50.780.250.150.480.410.170.80.720.530.770.86-0.44
0.970.920.830.520.930.190.320.420.590.730.89-0.150.980.860.670.60.880.850.660.810.880.98-0.040.71-0.28
0.90.870.720.350.930.00.330.370.430.680.8-0.230.920.740.630.570.870.830.60.720.810.92-0.180.6-0.25
0.190.090.190.510.190.0-0.31-0.140.280.310.320.050.130.26-0.16-0.20.0-0.16-0.060.410.180.110.390.41-0.12
0.380.390.390.170.320.33-0.310.070.42-0.290.30.10.320.570.870.890.390.670.760.090.410.410.050.12-0.12
0.230.19-0.01-0.260.420.37-0.140.07-0.110.150.090.370.310.130.260.30.150.290.45-0.020.030.3-0.43-0.020.45
0.70.710.80.670.590.430.280.42-0.110.440.70.040.660.690.520.470.70.570.540.70.770.670.20.72-0.27
0.760.770.690.490.730.680.31-0.290.150.440.77-0.30.780.490.04-0.060.750.420.060.830.730.720.010.78-0.32
0.960.940.90.80.890.80.320.30.090.70.77-0.10.890.920.510.420.870.740.480.920.970.90.330.92-0.38
-0.18-0.21-0.220.06-0.15-0.230.050.10.370.04-0.3-0.1-0.24-0.01-0.060.0-0.3-0.170.22-0.29-0.2-0.220.26-0.040.75
0.980.960.90.50.980.920.130.320.310.660.780.89-0.240.830.650.580.950.850.630.830.930.99-0.090.73-0.33
0.910.850.850.780.860.740.260.570.130.690.490.92-0.010.830.750.680.770.840.670.790.90.870.370.77-0.39
0.660.610.620.250.670.63-0.160.870.260.520.040.51-0.060.650.750.990.610.870.910.360.610.72-0.110.24-0.21
0.580.540.540.150.60.57-0.20.890.30.47-0.060.420.00.580.680.990.540.820.930.250.520.65-0.170.15-0.12
0.950.980.910.480.880.870.00.390.150.70.750.87-0.30.950.770.610.540.840.560.810.950.95-0.090.75-0.37
0.860.850.780.410.850.83-0.160.670.290.570.420.74-0.170.850.840.870.820.840.740.630.820.9-0.050.52-0.38
0.620.560.560.170.660.6-0.060.760.450.540.060.480.220.630.670.910.930.560.740.270.530.67-0.20.220.15
0.880.860.830.80.810.720.410.09-0.020.70.830.92-0.290.830.790.360.250.810.630.270.890.830.290.92-0.53
0.970.980.960.720.880.810.180.410.030.770.730.97-0.20.930.90.610.520.950.820.530.890.940.210.87-0.44
0.990.970.910.530.980.920.110.410.30.670.720.9-0.220.990.870.720.650.950.90.670.830.94-0.050.72-0.35
0.090.050.150.77-0.04-0.180.390.05-0.430.20.010.330.26-0.090.37-0.11-0.17-0.09-0.05-0.20.290.21-0.050.47-0.27
0.810.830.780.860.710.60.410.12-0.020.720.780.92-0.040.730.770.240.150.750.520.220.920.870.720.47-0.39
-0.37-0.38-0.42-0.44-0.28-0.25-0.12-0.120.45-0.27-0.32-0.380.75-0.33-0.39-0.21-0.12-0.37-0.380.15-0.53-0.44-0.35-0.27-0.39
Click cells to compare fundamentals

Pharming Group Account Relationship Matchups

Pharming Group fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets255.6M419.1M396.9M425.8M462.9M486.0M
Short Long Term Debt Total58.1M162.2M161.6M166.7M171.5M180.1M
Other Current Liab20.3M58.8M32.0M42.3M51.8M54.4M
Total Current Liabilities114.1M77.0M46.7M59.7M78.0M46.5M
Total Stockholder Equity117.3M183.7M192.7M204.6M218.8M229.7M
Property Plant And Equipment Net16.3M21.7M33.1M39.1M33.5M35.1M
Current Deferred Revenue34.6M34.3M(44.4K)(56.2K)(64.7K)(61.4K)
Net Debt(16.1M)(43.3M)(30.1M)(40.6M)109.8M115.3M
Retained Earnings(333.4M)(317.5M)(269.4M)(256.4M)(265.3M)(278.5M)
Accounts Payable6.0M13.5M5.1M6.1M14.5M7.9M
Cash74.3M205.5M191.7M207.3M61.7M71.7M
Non Current Assets Total136.3M155.5M147.7M148.3M146.5M153.8M
Non Currrent Assets Other2.5M510.4K(303.4K)1.3M1.6M863.7K
Cash And Short Term Investments74.3M205.5M191.7M207.3M213.4M224.1M
Net Receivables26.3M19.2M15.9M19.6M32.1M33.7M
Common Stock Shares Outstanding67.4M68.3M70.1M70.7M657.0M689.9M
Liabilities And Stockholders Equity255.6M419.1M396.9M425.8M462.9M486.0M
Non Current Liabilities Total24.2M158.4M157.5M161.5M166.1M174.4M
Inventory16.2M21.2M27.3M42.3M56.8M59.6M
Other Current Assets2.6M5.0M2.6M2.5M13.8M14.4M
Other Stockholder Equity439.4M500.9M462.7M462.3M479.2M355.2M
Total Liab138.4M235.4M204.2M221.2M244.1M256.3M
Total Current Assets119.3M263.6M249.2M277.5M316.3M332.2M
Short Term Debt53.2M4.0M2.4M5.2M5.4M5.2M
Intangible Assets79.3M94.2M83.8M75.1M71.3M43.1M
Common Stock7.1M7.9M7.3M7.5M6.9M6.6M
Accumulated Other Comprehensive Income4.2M5.3M2.2M(8.7M)(2.1M)(2.0M)
Other Liab32.7M17.3M173K146K131.4K124.8K
Net Tangible Assets38.2M77.2M96.2M129.5M148.9M156.4M
Long Term Debt0.0121.9M122.6M131.6M136.6M95.7M
Capital Lease Obligations6.3M8.3M18.4M33.3M33.1M34.8M
Deferred Long Term Liab2.2M4.3M4.4M266K239.4K227.4K
Net Invested Capital150.3M273.0M294.5M338.0M357.2M258.8M
Short Long Term Debt45.6M1.7M1.7M1.8M1.8M1.7M
Non Current Liabilities Other32.0M17.3M173K146K131.4K124.8K
Net Working Capital4.6M151.8M178.8M217.8M238.4M134.2M
Property Plant Equipment14.5M17.6M29.3M39.1M45.0M47.3M

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.